7th International Conference on Clinical Cancer Prevention 2012 with Consensus Co

2012 年第七届临床癌症预防国际会议与共识公司

• 批准号: 8400378
• 负责人: FRANK L. MEYSKENS
• 金额: $ 2万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-03-01 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8400378
• 关键词: 5 Alpha-Reductase Inhibitor; Accreditation; Age; American Medical Association; Aspirin; Aspirin Like Agents; Award; Biological Markers; Biological Models; Breast; Breast Cancer Prevention; Cancer Burden; Cancer Control; Carcinogens; Charge; Chemoprevention; Clinical; Collaborations; Colon Carcinoma; Colorectal Cancer; Communities; Consensus; Consensus Development; DL-alpha-Difluoromethylornithine; Data; Dietary Supplementation; Disabled Persons; Discipline; Educational Activities; Environment; Epidemiology; Europe; Faculty; Fees; Funding; General Population; Genomics; Goals; Human Papilloma Virus Vaccine; Individual; Influentials; International; Journals; Judgment; Knowledge; Laboratories; Lead; Location; London; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Malignant neoplasm of esophagus; Malignant neoplasm of prostate; Mind; Mission; Molecular Target; Non-Steroidal Anti-Inflammatory Agents; Nonprofit Organizations; Nutrient; Oral; Oxidoreductase; Participant; Pharmacologic Substance; Policies; Prevention; Prevention Research; Preventive; Prostate Cancer therapy; Public Health; Publishing; Recommendation; Reporting; Request for Applications; Research; Research Personnel; Resources; Risk; Route; Science; Scientist; Series; Side; Smoke; Societies; Sulindac; Switzerland; Training; Travel; Underrepresented Minority; United Kingdom; Vitamin D; Vitamin E; Woman; Work; abstracting; base; cancer prevention; carcinogenesis; career; cost; discount; high risk; improved; inhibitor/antagonist; interest; lycopene; meetings; posters; prostate cancer prevention; public health relevance; research and development; social; symposium

DESCRIPTION (provided by applicant): ISCaP, the International Society for Cancer Prevention is a non-profit organization founded in 1995 with a mission to provide an international forum for research and development in cancer prevention, promote interaction among laboratory, epidemiological and clinical researchers in cancer prevention and conduct educational activities to enhance professional and public understanding of cancer prevention. ISCaP has so far organized 6 biennial Clinical Cancer Prevention meetings with special focus on bridging the gap between laboratory-based prevention activities in model systems and large scale clinical projects, such as the major prevention trials which have a more public health focus. The 7th biennial meeting will be held in London, United Kingdom from 24th to 26th September 2012. This meeting aims to review evidence on current options for prevention of major cancers, facilitate interaction among scientists in the field of cancer prevention, stimulate research collaborations, and introduce in-training scientists and clinicians to the field. It will lso evaluate current evidence relating to chemoprevention of prostate cancer and draft a consensus statement on recommendations for research and practice. The meeting will be held at smoke-free and fully- accessible conference facilities, childcare facilities will be provided at the venu. The meeting spread over 3 days will comprise of standalone presentations, panel discussions, interactive session for junior researchers and consensus development session. About 40 speakers from diverse disciplines have been chosen on the basis that they are widely acknowledged as leader in their field and their work is relevant to cancer prevention and they will cover wide-ranging topics from carcinogenesis, biomarkers, molecular targets, infectious carcinogens, various preventive therapies to implementation and policy issues. Meeting will be widely publicized through various routes and abstracts will be solicited several months prior to the meeting, 30 top-ranked abstracts will be selected for presentation, 6 as oral and 24 as poster. An interactive session has been specially planned to stimulate and attract junior researchers to the field, and 4 junior researchers will also receive complementary registrations, others will be charged discounted registration fees. We anticipate that approximately 250 delegates will participate in this meeting and to attract women, underrepresented minority and disabled delegates, 6 more complementary registrations will be awarded. Europe-wide CME accreditation will be obtained; these credits are also recognized by the American Medical Association. In view of limited resources and considerable expenses required for the meeting we request funding support from NCI, these funds will specifically be used to partially cover travel costs of US-based faculty. The meeting will bring together cancer prevention researchers from all over world in a conducive and interactive environment that will promote scientific dialogue and exchange of ideas and attract young minds to the field to further cancer prevention research.

描述（由申请人提供）：ISCaP，国际癌症预防协会是一个非营利组织，成立于1995年，其使命是为癌症预防的研究和发展提供一个国际论坛，促进实验室，流行病学和临床研究人员在癌症预防方面的互动，并开展教育活动，以提高专业和公众对癌症预防的理解。到目前为止，国际癌症协会已经组织了6次两年一次的临床癌症预防会议，特别侧重于弥合模型系统中基于实验室的预防活动与大规模临床项目之间的差距，例如更注重公共卫生的主要预防试验。第七届双年度会议将于2012年9月24日至26日在联合王国伦敦举行。本次会议旨在审查目前预防主要癌症的选择的证据，促进癌症预防领域科学家之间的互动，促进 研究合作，并介绍在培训科学家和临床医生的领域。它还将评估目前有关前列腺癌化学预防的证据，并起草一份关于研究和实践建议的共识声明。会议将在无烟和完全无障碍的会议设施中举行，会场将提供托儿设施。会议为期3天，包括独立演讲、小组讨论、初级研究人员互动会议和共识发展会议。来自不同学科的约40位演讲者被选中，他们被广泛认为是各自领域的领导者，他们的工作与癌症预防有关，他们将涵盖从致癌作用，生物标志物，分子靶点，传染性致癌物，各种预防性治疗到实施和政策问题的广泛主题。会议将通过各种途径广泛宣传，并将在会议前几个月征集摘要，将选出30篇排名靠前的摘要，其中6篇为口头摘要，24篇为海报摘要。一个互动会议已特别计划，以刺激和吸引初级研究人员到该领域，4名初级研究人员也将获得补充注册，其他人将收取折扣注册费。我们预计将有大约250名代表参加这次会议，为了吸引妇女、代表人数不足的少数民族和残疾人代表，将再提供6名补充登记。将获得欧洲范围内的CME认证;这些学分也得到美国医学会的认可。鉴于会议所需的资源有限和相当大的费用，我们请求NCI提供资金支持，这些资金将专门用于支付美国教师的部分差旅费。会议将汇集来自世界各地的癌症预防研究人员在一个有利的和互动的环境，将促进科学对话和思想交流，并吸引年轻人到该领域进一步开展癌症预防研究。